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This study looked at incidence and outcome of refractory Status Epilepticus 
(RSE) admitted to ITU facilities in Glasgow between 1995 and 2013.  
 
Results 
Eight hundred cases were identified, with adequate information available in 633. 
Cases were separated depending on whether there had been previous epilepsy 
(SEPE, n=214) or De Novo Status Epilepticus (DNSE, n=419). 
The rising rates of RSE between 1995 and 2013 mirrors that seen in previous 
studies, and occurs in both SEPE and DNSE. There was no association of 
incidence of SEPE with any particular AED. Causes in both groups were listed, 
with 52% of those with DNSE having some contribution from substance misuse. 
In SEPE, this was felt to play a role in 33.7%.  
Duration of stay in both groups was similar, but the longest in-patient stays were 
in the DNSE group. Admission mortality in both groups was significantly higher 
in DNSE than in SEPE (13.8% versus 7.5%). This mortality risk was most closely 
associated with substance misuse in the group with DNSE. 
 
Conclusion 
Status Epilepticus is a medical emergency, but even after the acute phase is over, 
the risk of mortality stays high. De Novo Status Epilepticus has a worse 
prognosis than SE complicating previous epilepsy. The sustained rise in the risk 
of mortality should cause us to adopt a holistic method of care for our patients 
wit Refractory Status Epilepticus, particularly where there is a background of 









Status epilepticus (SE) is defined as continuation of seizures for more than 5 
minutes (Trinka et al 2015) and is a medical emergency that requires immediate 
assessment and treatment (SIGN 2015). Subdivision of stages of SE have been 
defined depending on the degree of response to treatment and duration of 
treatment needed. Refractory status epilepticus (RSE) is SE that continues 
despite treatment with benzodiazepines and at least one antiepileptic drug, 
while Super Refractory Status Epilepticus (SRSE) consists of continuous or 
recurrent seizures lasting for 24 h or more despite administration of an 
intravenous (IV) anaesthetic, or recurrence of SE on weaning from anaesthesia 
(Trinka e Kälviäinen, 2017).  
 
Preclinical studies show that persisting epileptic activity leads to changes in 
GABAergic function, increased glutamatergic stimulation, as well as changes in 
mitochondrial function and receptor trafficking, leading to a rapid escalation of 
epileptogenicity with persisting epileptic activity (Chen and Wasterlain 2006, 
Kapur and Macdonald 1997, Shorvon et al 2007). Such SE-related changes may 
underly the morbidity and mortality of prolonged seizures.  
 
There are many recognised causes of status epilepticus (Trinka 2012, Tan et al  
2010) and in approximately 50% of cases, this will be the first presentation of 
seizures or epilepsy .  
 
The risk factors for morbidity and mortality related to SE have not previously 
been well-defined, although small cohort studies  (Shorvon e Ferlisi, 2011),  
(Sutter et al., 2013), (Novy et al., 2010), (Kämppi et al., 2013) have suggested 
that older age at onset, generalised seizure at onset, treatment delay, impaired 
consciousness at presentation, or lack of EEG monitoring may all impair 
prognosis.  
 
Several studies (Novy et al., 2010), (Logroscino et al., 1997), (Kantanen et al., 
2017) have shown an immediate mortality of SE of between 7 and 39%, while 
long term mortality has been shown to be higher at 35-43%  (Shorvon e Ferlisi, 
2011) Logroschino 2002,  (Kantanen et al., 2017).  
 
It has been suggested that RSE has a higher short-term and long-term mortality 
than SE, although this is not invariably replicated (Kantalen 2017). The increased 
1-year mortality in SRSE has been associated with older age, or poorer 
neurological status on discharge from hospital (Kantalen 2017) 
 
Other studies have looked at incidence of SE, but we wanted to look at patients 
with SE which had been sustained enough to merit admission to an ITU setting, 
each one thereby fulfilling the definition of RSE,  and in some cases SRSE. This 
study looked at the incidence of RSE spanning the decades following the 
introduction of newer AEDs. We aimed to consider the effect of different baseline 
AEDs and assess the management and outcome of SRSE lasting for very extended 
periods (this will be discussed in a subsequent paper). 
 
We had hypothesised that increasing use of newer antiepileptic drugs (AEDs), 
with their more predictable pharmacokinetics, would reduce the incidence of 








The NHS GGC Research Ethics Committee was contacted and gave permission for 
this study to continue without a full ethics submission. 
Between 2013 and 2016, coding records were searched across NHS Greater 
Glasgow and Clyde for adults over the age of 16 years admitted to an Intensive 
Care Facility in any of the hospitals in Glasgow. Local records from the ITU in the 
Institute of Neurological Science provided additional data. 
Coding for admission depended on the international methods. ICD9 codes, which 
were until 31st March 1996, had no specific code for Status Epilepticus. From April 
1996, ICD 10 codes were used, and we sought admissions to ITU, HDU and CCU 
with primary diagnosis of ICD10 codes G40 (‘Epilepsy’), G41 (‘Status Epilepticus’) 
& R568 (‘Other & Unspecified Convulsions’). 
Patients with a final diagnosis of Pseudostatus Epilepticus or prolonged 
dissociative attacks are exclude from this audit but will be presented separately 
in a later paper. Separate publications will outline the treatments used and their 
effects. 
Demographic information was collected in each case. The outcome after 
admission was recorded, and for each case we recorded death during admission, 
at 1 years after admission, and - where appropriate - 5 years and 10 years after 
admission. 
Where patients had died more than 5 years before coding identification, paper 
records would have been destroyed, leaving only electronic records available. 
Where necessary, demographic and admission data was collected from the NHS 
GGC audit department (n=280) (Table 1 shows the minimum data available for 
every patient).  
Those presenting with RSE who had no prior diagnosis of epilepsy were termed 
De Novo Status Epilepticus (DNSE). Those who had a prior diagnosis of epilepsy 
were designated SE with Prior Epilepsy (SEPE). The causes, treatments, and 
outcomes (including short-term and long-term mortality) of those with DNSE 
and SEPE were compared. 
The existence of alcohol or drug dependency was either noted from a direct 
statement to that effect or inferred from other supporting information (eg 
previous admission for detoxification, deranged LFTs before admission, ongoing 
treatment with methadone, or treatment required for alcohol withdrawal 
syndrome). 
The Glasgow incidence of SE-related admissions per 100,000 was calculated 
using population estimates for Greater Glasgow from the census nearest the mid 
point of the sample incidence, being the 2011 census figure of 577,869.  Statistical 
comparisons were carried out using Microsoft Excel 2016 and Mini Tab version 
18. Comparison of mortality rates in groups was carried out using a Two Tailed Z 








A total of 800 admissions to ITU with relevant diagnostic codes were identified. 
We excluded 167 cases with insufficient information available, or with no 
supportable diagnosis of RSE. Six hundred and thirty-three admissions to ITU 
with RSE were identified, with 214 (34%) patients having experienced prior 
seizures or a diagnosis of epilepsy (Status Epilepticus with Previous Epilepsy – 
SEPE). 419 (66%) patients were admitted to an ITU for an index seizure (De 
Novo Status Epilepticus - DNSE).  
The nature of the SE was assessed: 590 (93.20%) being convulsive SE, and 24 
(3.79%) were focal SE. Thirteen cases (2%) were eventually thought to be non-
convulsive SE. In 6 cases (0.9%) no information on type of SE was available. 
 
Demographic Information 
The demographic details of the whole cohort and subgroups are shown in Table 
2. Age and gender distributions were similar in both DNSE and SEPE groups. 
There was a male preponderance in both groups, which may reflect the incidence 
of causative factors seen in subsequent tables. The incidence of alcohol-related 
problems was slightly higher in DNSE than among SEPE patients. Analysis of 
addiction issues and other risk factors (Table 2b) show increased rates related 
solely to addiction and abuse in the group with DNSE compared to SEPE (41% 
versus 18%). A more detailed breakdown of cause is shown later.  
 
Annual Incidence 
The annual number of cases of RSE (both SEPE and DNSE) in Glasgow is shown 
in Table 3. The wide variation is noted, and we have for clarity formed 3-year 
cohorts (Figure 1). Both DNSE and SEPE show a parallel pattern of a steady 
rising incidence up to the 2007-09 epoch, peaking at just under 20/100,000 per 
year followed by a slight drop.  
 
Baseline AED Treatment  
Among 191 cases with SEPE, 170 (89%) were being prescribed AEDs at the time 
of admission, but the exact nature of this treatment was only known in 163 
patients. Of these, 93 (57%) were receiving only established AEDs, with 24 
(14.7%) solely on new AEDs and 46 (28%) on a mixture of established and new 
AEDs.  
Table 4 and Figure 3 show baseline AED use in patients with SEPE before and 
after 2003. In later years the use of newer AEDs increases markedly. AED use 
was also grouped by effect on hepatic enzymes (Table 5). Enzyme inducing AEDs 
(EIAEDs - Carbamazepine, phenytoin, phenobarbitone and primidone) were 
being prescribed in 104 (63.8%) at the time of admission. Valproate (Figure 3) 
was the single most commonly prescribed AED, used in 68 patients (41.7%). 
Phenytoin was the second most commonly prescribed (n=53, 32.5%) and 









Identified Causes of SE 
Where specific causes were identified, these are listed in Table 6. As expected, 
SEPE and DNSE have a different spread of contributory and causative factors.  
Provocation by alcohol +/or drug misuse is significant in 54.9% of those with 
DNSE and 33.7% of those with SEPE. In the SEPE group a wide range of causes 
was found. In those with a prior diagnosis of epilepsy, the progressive nature of 
the epilepsy syndrome and incomplete adherence or loss of effect of AED made 
up the majority of the SEPE. No cause was identified in 13.8%. 
 
Outcomes of RSE – Admission to ITU and Total Hospital Stay 
The median duration of stay in ITU (ie time to discharge or death) was similar in 
both groups, with more than half staying in for 2 days or less (Table 7). While the 
median stay is similar across SEPE and DNSE groups, 10.5% and 13% of those 
with DNSE and SEPE respectively had an ITU admission lasting longer than 7 
days or more. The longest-term stays arose only among those with DNSE, with 
0.31% requiring ITU admission for longer than 6 weeks. Median duration of total 
in-patient hospital stay was slightly longer in DNSE (10 versus 6 days), which 
was also associated with the longest stays.  
 
Outcomes of RSE – Death, Residual Neurological Deficit, or Full Recovery 
As can be seen in Table 8 and 9, the admission mortality rate was higher in DNSE 
than SEPE (14% versus 7.5%) (p=0.0195 CI 1%-11.59%). At one-year, 5 years 
and 10 years post admission post- admission, this significant difference in 
mortality had persisted, (Table 8+9).  
Where information was available (Table 10), we looked at the discharge status, 
showing incidence of full recovery in those with DNSE (31.3%) and SEPE 
(24.4%). Among those surviving the admission, the percentages with and 
without neurological deficit were very similar in both DNSE and SEPE, with one 
third in each group surviving without neurological deficit.  
 
Outcomes of RSE - Risk of Subsequent Epilepsy 
One hundred and thirty four patients with DNSE (37%) were started on long 
term AEDs, and could be inferred as having developed epilepsy.  Where alcohol 
and/or drug misuse was seen as a sole single cause of SE, 48/171 (28%) of 
patients ended up being on long term AED. Eight of 16 patients with idiopathic 







We believe this is one of the largest studies of incidence and outcome of 
refractory SE (Misra et al 2017, Strzelczyk et al 2017, Kantanen 2017).  Using 
available records we attempted to assess the longitudinal incidence of SE in a 
single city over a period of almost two decades.  
 
The criteria for recruitment (ie requiring treatment in an ITU setting) ensures 
that these cases are at least Refractory SE (rSE) with 303 (48%)% fulfilling the 
criteria for Super Refractory SE. The morphology of SE is similar that seen in 
other studies, but the focus on ITU treatment ensures that there is a 
preponderance of convulsive SE.  
 
We have separated out the groups depending on a prior history of seizures and 
think that the approach has been validated by demonstration of the differences 
between the groups in causation and outcome.  
A male preponderance is common to both groups which appears unusual in 
studies of SE (Knake et al 2001, Strzelczyk et al 2017,). The study by Strzelczyk 
et al (2017) made no mention of the incidence of addiction or substance abuse in 
its cohort.  
In Glasgow over the period 1995-2013 there was an increasing incidence of RSE, 
involving both DNSE and SEPE. The fact that DNSE also increases avoids any 
suggestion that the increase in SEPE is caused by a decreased effectiveness of 
newer AEDs. An increasing incidence has also been shown in studies of SE in 
other populations (Nelligan and Walker 2016, Wu et al 2002, Dham et al 2014), 
and it has been postulated that it is increasing identification and treatment that 
explains the decreasing mortality from SE in England and Wales (Nelligan and 
Walker 2016). While such increasing recognition of the need for emergency 
treatment of SE may be widespread, it may be especially focussed in Scotland 
with the adoption of national guidelines –the first SIGN guidance in 1997, with 
updates coming in 2003 and later 2015 (SIGN 1997, SIGN 2003, SIGN 2015) 
emphasising the need for emergency care.  
Studies of SE (Knake 1997, Hesdorffer 1998, Coeytaux 2000, Jallon 1999) have 
suggested an annual incidence of 17-20/100,000, which is similar to the peaking 
incidence of RSE of all causes in our population. In our study the incidence of RSE 
is in keeping with other geographical studies of RSE (Kantanen 2017). Our data 
would suggest a similar incidence of SRSE, at 2.7/100,000, to that described by 
Kantanen ( 2017).  
   
The pattern of SE noted in our population was similar to other studies of adults 
(Knake 2001), with the majority of cases comprising convulsive SE.  In those 
with SEPE, there was no particular emergent pattern of AED use when looking at 
individual AEDs or when grouping by effect on hepatic enzymes. The increasing 
use of newer AEDs in SEPE was unsurprising, and is in keeping with the 






Mortality of refractory Status Epilepticus  
As can be seen in Table 8 and 9, the admission mortality rate was higher in DNSE 
than SEPE (14% versus 7.5%). The other large study of RSE suggested an 
admission mortality of around 15% across all cases of RSE (Strzelczyk et al 
2017). One year post- admission, this difference in mortality rates in DNSE and 
SEPE was maintained, but expanded in subsequent years, such that 5 years after 
admission 41.5% of DNSE had died compared to 27.6% of those with SEPE. It 
may have been anticipated that refractory SEPE would respond better then those 
with DNSE, since many of these would be related to reversible causes.  
By one year post-admission, mortality rates in our cohort are considerable, 
exceeding the 25% shown by Kantanen et al (2017).  
Most of the RSE-associated mortality arises in the first few years. Mortality from 
SEPE and DNSE was significant during admission, being twice as common in the 
former group. The difference in mortality expanded over the next 5 years, such 
that 5 years after admission 41.5% of DNSE had died compared to 27.6% of 
those with SEPE.  
 
Causes of RSE-Associated mortality  
The prognosis of RSE is said (Neligan and Shorvon 2011), to depend on the 
duration of seizures and the underlying cause. In our study, addiction and 
substance abuse issues are associated with an increased admission and 
subsequent mortality in both DNSE and SEPE. It may have been presumed that 
simple avoidance of any risk factor for directly provoked seizures (ie alcohol and 
/ or drugs) would reduce mortality, but our data does not reflect this. Table 10 
and 11 show the contribution of addiction and abuse to deaths in the group with 
DNSE and SEPE. At each time point, alcohol and drugs comprise the largest 
contributor to mortality. In those with SEPE (Table 11) alcohol and drug use 
comprise a less striking contributor to mortality.  
 
The causes of the two groups of RSE are predictably different: in SEPE, the better 
outcome may signal the presence of a reversible cause of epilepsy exacerbation.  
In DNSE, our data suggests that underlying addiction or abuse issues are not a 
simple reversible cause or exacerbation but are in fact a negative prognostic 
marker for long term mortality. In the DNSE group 28% of all deaths within 1 
year were related to alcohol and drug-related complications, increasing to 34.4% 
of all deaths over 10 years.  In the SEPE group, 1 year mortality was 20.2% , with 
31.6% dying because of seizures over 10 years  
 
Despite the longer admission with DNSE, the rate of full neurological recovery 
was similar in those with DNSE and SEPE. This risk of residual neurological 
deficit despite ‘milder’ RSE may reflect the cause of the underlying epilepsy in 




In patients with DNSE, this index seizure was followed by a need for AEDs in 
37%, a level of recurrence which would confirm that an index episode of SE or 
RSE is no more liable to lead to a recurrence and need for AEDs than a single 
shorter seizure (Marson 2005).  
 
Neurological Disability 
Previous studies of SE among adults (Cascino 1998) have suggested neurological 
deterioration in only 3.3% among those surviving at least 30 days. Neurological 
deterioration in children with SE appears to be higher (Nelligan and Shorvon 
2011). While the rates of neurological deficit are raised in both DNSE and SEPE, 
in neither does the level of disability approach that in another larger study 






We think the study of this group of similarly and consistently severe status 
epilepticus is important. Firstly we think that the separation of DNSE from SEPE 
is helpful in beginning to delineate prognosis, the need for further investigation, 
and the role of ineffective or absent AEDs in causation. The mortality rate of RSE 
is high, and importantly it represents a call to action for the medical community. 
The significantly greater admission mortality with DNSE, which persists in the 
years following discharge should confirm that SE with a background of addiction 
or abuse should not simply be considered as a ‘provoked seizure’ and treated 
with acute support and encouragement to abstinence. Instead it suggests that a 
presentation with DNSE is a sign of a system in peril, and that such episodes 
should spark off a chain of multispecialty care in order to address this recurring 












Figures and Tables 
 
Table 1  
minimum data set  
CHI number or hospital ID  
AGE  
SEX  
Year of SE  
Prior epilepsy or DNSE  
Length of ITU STAY  
Date of hospital admission  
Date of ITU admission  
Date of ITU discharge  
Date of hospital discharge  
Date of death  
Death after number of days from ITU d/c 
 
  
Table 2 Demographic Data: 
 
 

























Documented Drug abuse  103 (16%) 71 (17%) 32 (15%) 
Documented Alcohol abuse  312 (49%) 227 (54%) 85 (40%) 





27 (6.4%) 81 (38%) 




(0.5 – 1497) 
28, 10 
(0.5 – 1497)  
 
8.7, 6 
(0.5- 30)  
 









Number of Deaths 303 (47.86%) 220 (52.5%) 83(38.7%) 
Deaths during admission 74 (11.69%) 58 (13.8%) 16(7.47%) 
Deaths before 1-year post 
Admission (%age died / 
FOLLOW UP @1 YEAR) 
141 (22%) 106(25%) 35(16%) 















Type of status:    
Focal  24 (3.8%)    1O (2%) 14 (6%) 
GTCS 590 (93%) 395 (94%) 195 (91%) 
Not Known 6 (0.9%) 6 (1.5%) 0 
NCSE 13 (2%) 8 (2%) 5 (2.3%) 
Cause of Status:    
Alcohol & Drugs 210 (33.17%) 171 (41%) 39(18.2%) 
Multiple including alcohol 
and drugs 
82 (13%) 48 (11.5%) 34 (15.2%) 
Others non-alcohol and drugs 
related causes 
308 (48.65%) 179 (42.7%) 129 (65.9%) 
No information  33 (5.2%) 21 (5%) 12(5.6%) 
Continued AED 310 (55.45%) 134 (37%) 176 (89%) 
 
Table 3 – Annual No Of Cases of Status Epilepticus in Glasgow 1995-2013 
 
Year Total Number SEPE DNSE 
1995 13 2 11 
1996 1 0 1 
1997 24 8 16 
1998 12 1 11 
1999 23 5 18 
2000 29 8 21 
2001 34 12 22 
2002 43 15 28 
2003 29 7 22 
2004 34 14 20 
2005 41 16 25 
2006 51 17 34 
2007 55 21 34 
2008 55 22 33 
2009 59 18 41 
2010 28 13 15 
2011 49 17 32 
2012 35 9 26 
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Figure 1





Figure 2 – Nature of Baseline AED (n=163) 
 
         Old AEDs =Phenytoin, Carbamazepine, Sodium Valproate 












Table 4 – Nature of Baseline AED in SEPE Group by Year of Admission 
 
 








45 11 57 42 5 22 13 31 4 23 
CBZ=Carbamazepine, VPA=Valproate, PHT=Phenytoin, GBP=Gabapentin, 














Enzyme inducer monotherapy 12 26 
Non-Enzyme Inducer monotherapy 2 30 
Polytherapy including Enzyme inducing AED 8 53 














Sole Contributor = 










































































Progressive epilepsy syndrome n/a 
24 
(11.1%) 














Table 7 – Duration of Hospital and ITU Admission for SE 
  Total  DNSE SEPE 
ITU Stay (days)       
Median 1.0 1.0 2.0 
Mean 3.6 3.7 3.7 
Range  0.5-165 0.5-165 0.5-26 
1-7 days n(%) 556 (87.8%) 370 (88.3%) 186 (86,2%) 
 >7 days  n(%) 72 (11.4%) 44 (10.5%) 28 (13.8%) 
>28 days n(%) 3 (0.5%) 3 (0.7%) 0 
>42 days n(%)  2 (0.3%)  2 (0.5%) 0  
      
 Hospital Stay (days)       
Median 8.0 10.0 6.0 
Mean 21.4 28.0 8.7 
Range  0.5-1497 0.5-1497 0.5-30 
1-7 days n(%) 146 (23.1%) 23 (5.5%) 123 (57.5%) 
 >7 days  n(%) 330 (52%) 240 (57.3%)  90 (42%) 
>28 days n(%)  92 (14.5%) 91 (21.7%)  1 (0.5%) 




Table 8 -  Year of Death After SE Admission  
Years                                DNSE Deaths                          SEPE Deaths  
0 year 58 16 
1 year  48 19 
2 years 22 7 
3 years 24 11 
4 years 8 7 
5 years 14 4 
6 years  13 2 
7 years  10 4 
8 years  3 6 
9 years  4 3 
10 years  2 0 
 
  
Table 9  - Cumulative Mortality Over 10 years  
  
 Total Cohort DNSE SEPE p-value 
CI for Difference 




74 (11.69%) 58 (13.8%)** 16(7.47%)** P=0.02 
1%-11.6% 
Deaths at 1-year 
post SE  
141 (22%) 106(25%)** 35 (16%)** P=0.011 
2.1%-15.8% 
Deaths at 5-year 
post SE  







Deaths at 10 -
year post SE  
285 (45%) 206 (49%)** 79 (37%)** P=0.0033 
4.1%-20.5% 
































0 year 1 year 2 years 3 years 4 years 5 years 6 years 7 years 8 years 9 years 10
years
Deaths over 10 years post SE 
DNSE Deaths Known Epilepsy Deaths
 
 
















































 Cause of 
death 2-3-
year post SE 
(n=46) 
 Cause of 
death 4-5-
year post SE 
(n=22) 
 Cause of 
death 5-10-





16 Alcohol & 
drugs 
14 Alcohol & 
drugs 
17 Alcohol & 
drugs 
10 Alcohol & 
drugs 
14 
CVD, ICH 9 Malignancy 8 Sepsis  8 Sepsis  4 Malignancy  5 
Encephalitis  7 Sepsis 6 Malignancy  8 Malignancy 4 CVS 3 
Seizure  7 CVD 6 Seizure  4 PVD 1 CVD 3 
CVS 7 Seizure  4 CVD, ICH 4 CVS 1 Metabolic 2 
 
CVD= cerebrovascular disease, ICH= intracerebral haemorrhage, CVS= 
cardiovascular , PVD= peripheral vascular disease    
 
 












 Cause of 
death 2-3-
year post SE 
(n=18) 
 Cause of 
death 4-5-
year post SE 
(n=9) 
 Cause of 
death 5-10-
year post SE  
(n=17) 
 
Seizures  7 Seizures  9 Seizures 9 Alcohol and 
drugs 
3 CVS 4 
Alcohol and 
drugs  
3 Sepsis 3 CVD 4 Progressive 
degenerative 
disease 
2 Seizures 4 




1 Alcohol and 
drugs 
2 Alcohol and 
drugs 






1 Suicide  1 Metabolic 1 Unexplained  1 
 
CVD= cerebrovascular disease, ICH= intracerebral haemorrhage, CVS= 







Cascino, G.D., Hesdorffer, D., Logroscino, G., Hauser, W.A., Morbidity of nonfebrile  
Epilepsia 1998; 39: 829—832. 
 
Chen JW and Wasterlain CG. Status Epilepticus: pathophysiology and 
management in adults. Lancet Neurology 2006; 5: 246-256 
 
Coeytaux A, Jallon P, Galobardes B, et al. Incidence of status epilepticus in French 
speaking Switzerland (EPISTAR). Neurology 2000;55:693–7. 
 
Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the 
United States. Neurocritical Care 2014; 20:476-83 
 
Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in 
Rochester, Minnesota, 1965–84. Neurology 1998;50: 735-41 
 
Jallon P, Coeytaux A, Galobardes B, et al. Incidence and case fatality rate of status 
epilepticus in the Canton of Geneva. Lancet 1999;353:1496. 
 
Kamppi L, Mustonen H, Soinila S. Analysis of the delay components in thetreatment 
of status epilepticus. Neurocrit Care. 2013;19:10–8. doi:10.1007/s12028-013-9862-x 
 
Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and 
Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. Journal of 
Neuroscience 1997 ; 17: 7532-40  
 
Leach JP, Mohanraj R, Borland W.  Alcohol and drugs in epilepsy: 
Pathophysiology, presentation, possibilities, and prevention.  
Epilepsia 2012;53 (Suppl 4): 48-5 
 
Knake A, Rosenow F, Vescovi M et al for the Status Epilepticus Study Group Hessen 
(SESGH). Incidence of Status Epilepticus in Adults in Germany:- A Prospective, 
Population-Based Study. Epilepsia 2001; 42:714–718 
 
Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term 
mortality after a first episode of status epilepticus. Epilepsia 1997;38:1344–9 
 
Logroscino G, Hesdorffer DC, Cascino GD, Annegers JF, Bagiella E, Hauser WA. 
Long-term mortality after a first episode of status epilepticus. Neurology. 
2002;58:537–41 (need to look at this closely) 
 
Marson A, Jacoby A, Johnson A, et al, on behalf of the Medical Research Council 
MESS Study Group.  Immediate versus deferred antiepileptic drug treatment for early 
epilepsy and single seizures: a randomized controlled trial. Lancet 2005; 365:2007-13 
 
Nelligan A, and Walker MC. Falling status epilepticus mortality rates in England 
and Wales: 2001-2013. Epilepsia 2016; 57:e121-124    doi:10.1111/epi.13402 
 
Nelligan A, Shorvon S. Prognostic factors, morbidity and mortality in tonic—clonic 
status epilepticus: A review. Epilepsy Research 2011; 93:1—10 
 
Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective 
observational study. Epilepsia. 2010;51:251–6. doi:10.1111/j.1528-
1167.2009.02323.x. 
 
Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory 
convulsive status epilepticus and recommendations for therapy. Brain. 
2012;135:2314–28. doi:10.1093/brain/aws091 
 
SIGN 2015 – Diagnosis and Management of Epilepsy. SIGN Guidance 143  
www.sign.ac.uk 
 
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, 
Lowenstein DH. A definition and classification of status epilepticus – Report of the 
ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015 56:1515–
1523  doi: 10.1111/epi.13121 
 
Shorvon SD, Trinka E, Walker MC. The Proceedings of the First London 
Colloquium on Status Epilepticus – UCL. Epilepsia 2007; 48 (Suppl 8): 1-3 
 
Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. 
Costs, length of stay, and mortality of super-refractory status epilepticus: a 
population-based study from Germany. Epilepsia (2017) 58(9):1533–
41.10.1111/epi.13837 
 
Sutter R, Marsch S, Fuhr P, Ruegg S. Mortality and recovery from refractory status 
epilepticus in the intensive care unit: a 7-year observational study. Epilepsia. 
2013;54:502–11. doi:10.1111/epi.12064. 
 
Tan RY, Nelligan A, and Shorvon SD.  The uncommon causes of status epilepticus: 
a systematic review. Epilepsy Research  2010 ;91:111-22. doi: 
10.1016/j.eplepsyres.2010.07.015 
 
Trinka E, Hofler J, Zerbs A. Causes of status epilepticus.  
Epilepsia. 2012;53 Suppl 4:127–38. doi:10.1111/j.1528-1167.2012.03622.x 
 
Trinka E, Kalviainen R. 25 Years of advances in definition, classification 
andtreatment of status epilepticus. Seizure 2017 ;44:65–73 
 
Vooturia S, Jayalakshmia S, Sahub S, Mohandasa S.  
Prognosis and predictors of outcome of refractory generalized convulsive status 
epilepticus in adults treated in neurointensive care unit. Clinical Neurology and 
Neurosurgery 2014; 126 : 7–10  
 
Wu YW, Shek DW, Garcia PA et al. Incidence and mortality of generalised 
convulsive status epilepticus in California. Neurology 2002; 58: 1070-76 
 
KANTANEN, A. M.  et al. Long-term outcome of refractory status epilepticus in 
adults: A retrospective population-based study. Epilepsy Res, v. 133, p. 13-21, 
Jul 2017. ISSN 1872-6844. Disponível em: < 
https://www.ncbi.nlm.nih.gov/pubmed/28402834 >.  
 
KÄMPPI, L.; MUSTONEN, H.; SOINILA, S. Analysis of the delay components in the 
treatment of status epilepticus. Neurocrit Care, v. 19, n. 1, p. 10-8, Aug 2013. 
ISSN 1556-0961. Disponível em: < 
https://www.ncbi.nlm.nih.gov/pubmed/23817962 >.  
 
LOGROSCINO, G.  et al. Short-term mortality after a first episode of status 
epilepticus. Epilepsia, v. 38, n. 12, p. 1344-9, Dec 1997. ISSN 0013-9580. 
Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/9578531 >.  
 
NOVY, J.; LOGROSCINO, G.; ROSSETTI, A. O. Refractory status epilepticus: a 
prospective observational study. Epilepsia, v. 51, n. 2, p. 251-6, Feb 2010. ISSN 
1528-1167. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/19817823 
>.  
 
SHORVON, S.; FERLISI, M. The treatment of super-refractory status epilepticus: a 
critical review of available therapies and a clinical treatment protocol. Brain, v. 
134, n. Pt 10, p. 2802-18, Oct 2011. ISSN 1460-2156. Disponível em: < 
https://www.ncbi.nlm.nih.gov/pubmed/21914716 >.  
 
SUTTER, R.  et al. Mortality and recovery from refractory status epilepticus in the 
intensive care unit: a 7-year observational study. Epilepsia, v. 54, n. 3, p. 502-11, 
Mar 2013. ISSN 1528-1167. Disponível em: < 
https://www.ncbi.nlm.nih.gov/pubmed/23294049 >.  
 
TRINKA, E.  et al. A definition and classification of status epilepticus--Report of 
the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, v. 56, n. 10, 
p. 1515-23, Oct 2015. ISSN 1528-1167. Disponível em: < 
http://www.ncbi.nlm.nih.gov/pubmed/26336950 >.  
 
TRINKA, E.; KÄLVIÄINEN, R. 25 years of advances in the definition, classification 
and treatment of status epilepticus. Seizure, v. 44, p. 65-73, Jan 2017. ISSN 1532-
2688. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/27890484 >.  
 
 
 
  
 
 
 
 
 
 
 
 
